MedTrace Logo

Prospective Epidemiological Study Of The Prevalence Of HLAB*5701 In HIV-1 Infected Patients

NCT00441688 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 974

Last updated 2017-08-22

No results posted yet for this study

Summary

This study is a cross sectional observational study to evaluate the prevalence of HLA-B\*5701 in the major French ethnotypes.

Any HIV-1 infected subject will be eligible for this study including antiretroviral therapy (ART) naÃ-ve and experienced subjects irrespective of abacavir use, as well as subjects previously tested for HLA-B\*5701. Subjects will be approached during a standard clinic visit, and all subjects will be consented prior to any study specific procedure. Subjects will be asked to provide a tissue sample (cheek cells and blood sample) which will be used to assess HLA-B\*5701 status by central and local methodologies.

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

GI265235

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · ViiV Healthcare

Study Design

Purpose
OTHER
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-15
Primary Completion
2007-06-01
Completion
2007-06-01

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00441688 on ClinicalTrials.gov